Overview: Pharmacokinetic Drug-Drug Interactions

Advances in Pharmacology

Volumn 43, Issue C, 1997, Pages 1-6

  Li, Albert P ^a   Jurima Romet, Malle ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b Bureau of Drug Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG DERIVATIVE; ISOENZYME; ORAL CONTRACEPTIVE AGENT; SORIVUDINE; TERFENADINE; URACIL ARABINOSIDE;

BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; FEMALE; HEART DISEASE; HUMAN; LIVER; METABOLISM; PHARMACOKINETICS; PREGNANCY; REVIEW; UNWANTED PREGNANCY;

ARABINOFURANOSYLURACIL; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEART DISEASES; HUMANS; ISOENZYMES; LIVER; PHARMACOKINETICS; PREGNANCY; PREGNANCY, UNWANTED; TERFENADINE;

EID: 0030627299     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60199-4     Document Type: Article

References (14)

1. Bolt H.M., Bolt M., and Kappus H. Interaction of rifampacin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocr. (Copenhagen) 85 (1977) 189-197
2. Carlson A.M., and Morris L.S. Coprescription of terfenadine and erythromycin or ketoconazole: An assessment of potential harm. J. Am. Pharm. Assoc. [N. S.] 36 (1996) 263-269
3. Crumb Jr. W.J., Wible B., Arnold D.J., Payne J.P., and Brown A.M. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity. Mol. Pharmacol. 47 (1995) 181-190
4. FDA (1997). Drug metabolism/drug interaction studies in the drug developing process: Studies in vitro. Guide for Industry, April 1997
5. Hansten P.D., and Horn J.R. "Drug Interactions & Updates." (1993), Applied Therapeutics, Inc., Vancouver, WA
6. Honig P.K., Woosley R.L., Zamani K., Conner D.P., and Cantilena L.R. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52 (1992) 231-238
7. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., and Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA J. Am. Med. Assoc. 269 (1993) 1550-1552
8. Jurima-Romet M., Huang H.S., Beck D.J., and Li A.P. Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicol. In Vitro 10 (1996) 655-663
9. Kato Y., Mori T., Ohmori K., and Ichimura M. Effect of terfenadine and KW-4679, a novel antiallergic compound, on action potential of guinea pig ventricular myocytes. Jpn. J. Pharmacol. 70 (1996) 199-202
10. Li A.P., Kaminski D.L., and Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104 (1995) 1-8
11. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., and Cantilena L.R. Torsades de pointes occurring in association with terfenadine use. JAMA J. Am. Med. Assoc. 264 (1990) 2788-2790
12. Okuda H., Nishiyama T., Ogura K., Nagayama S., Ikeda K., Yamagouchi S., Nakamura Y., and Watabe T. Mechanism of lethal toxicity exerted by simultaneous administration of the new antiviral sorivudine, and the antitumor agent tefafur. Xenobiotic Metab. Dispos. 10 (1995) S166-S169 Suppl
13. Pohjola-Sintonen S., Vitassalo M., Tolvonen L., and Neuvonen P. Itraconazaole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45 (1993) 191-193
14. Van Dijke C.P.H., and Weber J.C.P. Interaction between oral contraceptives and griseofulvin. Br. Med. J. 288 (1984) 1125-1126